Supernus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 652
- Market Cap
- $1.9B
- Website
- http://www.supernus.com
- Introduction
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
- Conditions
- ADHD
- Interventions
- Drug: PlaceboDrug: 200mg SPN-812Drug: 400mg SPN-812
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT03247517
- Locations
- 🇺🇸
Neuropsychiatric Research Center of Orange County, Orange, California, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Finger Lakes Clinical Research, Rochester, New York, United States
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
- Conditions
- ADHD
- Interventions
- Drug: 400mg SPN-812Drug: PlaceboDrug: 200mg SPN-812
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 313
- Registration Number
- NCT03247543
- Locations
- 🇺🇸
Bayou City Research Corporation, Houston, Texas, United States
🇺🇸Ericksen Research & Development, Clinton, Utah, United States
🇺🇸University of South Florida- Dept. of Psychiatry and Neurosciences, Tampa, Florida, United States
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
- Conditions
- ADHD
- Interventions
- Drug: PlaceboDrug: 100mg SPN-812Drug: 200mg SPN-812
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 477
- Registration Number
- NCT03247530
- Locations
- 🇺🇸
Aspen Clinical Research, Orem, Utah, United States
🇺🇸Advanced Clinical Research, Meridian, Idaho, United States
🇺🇸Finger Lakes Clinical Research, Rochester, New York, United States
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
- Conditions
- ADHD
- Interventions
- Drug: PlaceboDrug: 400mg SPN-812Drug: 600mg SPN-812
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 297
- Registration Number
- NCT03247556
- Locations
- 🇺🇸
Alliance for Wellness dba Alliance for Research, Long Beach, California, United States
🇺🇸Meridien Research at Florida Clinical Research Center, Bradenton, Florida, United States
🇺🇸Miami Clinical Research, Miami, Florida, United States
Bioavailability, Safety, and Tolerability of BIS-001 ER
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03156439
- Locations
- 🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 1400
- Registration Number
- NCT02736656
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Alliance for Wellness dba Alliance for Research, Long Beach, California, United States
🇺🇸Florida Clinical Research Center, LLC., Maitland, Florida, United States
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 491
- Registration Number
- NCT02691182
- Locations
- 🇺🇸
CNS Healthcare of Orlando, Orlando, Florida, United States
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PlaceboDrug: 100mg SPN-812Drug: 200mg SPN-812Drug: 300mg SPN-812Drug: 400mg SPN-812
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT02633527
- Locations
- 🇺🇸
Florida Clinical Research Center, LLC, Maitland, Florida, United States
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PlaceboDrug: SPN-810 (18 mg)Drug: SPN-810 (36 mg)
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 297
- Registration Number
- NCT02618434
- Locations
- 🇺🇸
Gulfcoast Clinical Research Center, Fort Myers, Florida, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Pedia Research, Owensboro, Kentucky, United States
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PlaceboDrug: SPN-810 (36 mg)Drug: SPN-810 (18 mg)
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT02618408
- Locations
- 🇺🇸
Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, Maryland, United States
🇺🇸Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸Meridien Research at Florida Clinical Research Center, Bradenton, Florida, United States